Island Pharmaceuticals Limited (ASX:ILA)

Australia · Delayed Price · Currency is AUD

0.3300

+0.0050 (1.54%)

Nov 9, 2026, 1:58 PM AEDT

Market Cap	97.71M -15.7%
Revenue (ttm)	282.66K +137.7%
Net Income	-9.84M
EPS	-0.04
Shares Out	296.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	190,451
Open	0.3400
Previous Close	0.3250
Day's Range	0.3275 - 0.3400
52-Week Range	0.2600 - 0.6300
Beta	0.13
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 25, 2026

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company’s lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol ILA

Full Company Profile

Financial Performance

In fiscal year 2026, Island Pharmaceuticals's revenue was 282,657, an increase of 137.71% compared to the previous year's 118,910. Losses were -9.84 million, 151.1% more than in 2025.

Financial Statements